IMULAN Creates Clinical Website For Veterinarians

Main Category: Veterinary
Article Date: 08 Oct 2008 - 3:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

5 (1 votes)

Healthcare Prof:not yet rated


Imulan BioTherapeutics, LLC (IMULAN) announced they have launched a new clinical trial website, http://www.IMULANtrials.com, to accommodate their growing comparative research and clinical trial program. The new website will provide veterinarians information regarding IMULAN's ongoing and future trials, including trials for atopic dermatitis, feline stomatitis, asthma, leukemia virus, and other diseases associated with infections or immune mediated disorders.

About the Technologies

Imulan is developing three immune regulating technologies for veterinary medicine, being LTCI, ImSAIDs, and TCR Vax.

LTCI: Lymphocyte T-Cell Immunomodulator is a biologic that has received a conditional license as a treatment aid for Feline Leukemia Virus (FeLV) and Feline Immunodeficiency Virus (FIV) infections and their associated symptoms including opportunistic infection and anemia.

ImSAIDs: The Immune Selective Anti-Inflammatory Derivatives are rapidly acting, orally active natural biological peptides that are being investigated for their use in controlling inappropriate immune responses associated with sepsis, anaphylaxis, acute trauma, pancreatitis, cystitis, allergies and asthma.

TCR Vax: T-Cell Receptor Peptide Vaccines modulate T-helper cell responses, including restoring immune function in aged animals and restoring Th1/Th2 cytokine signaling profiles. TCR Vax is a lead candidate for canine atopic dermatitis and has recently shown promise in feline stomatitis.

About Imulan

Imulan develops unique, precision immune regulating compounds for veterinary medicine. Imulan's primary focus is on biological strategies that combine peptide pharmacology with immunology to treat infectious, autoimmune, and immune mediated diseases in small and large animal medicine. IMULAN recently commercialized Lymphocyte T-Cell Immunomodulator as a conditionally licensed treatment aid for cats infected with feline leukemia and immunodeficiency virus.

Imulan

Article adapted by Medical News Today from original press release.
Visit our veterinary section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Imulan. "IMULAN Creates Clinical Website For Veterinarians." Medical News Today. MediLexicon, Intl., 8 Oct. 2008. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/124651.php>

APA
Imulan. (2008, October 8). "IMULAN Creates Clinical Website For Veterinarians." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/124651.php.

Please note: If no author information is provided, the source is cited instead.


Veterinary

Most Popular Articles



Follow Our Veterinary News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Veterinary Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »